There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come.
The market kicks off with Herbalife reporting quarterly results on Monday. Is the nutritional products company a pyramid scheme as Bill Ackman suggests? Is it a bargain as Carl Icahn implies by recently taking a sizable stake? We may not get any definitive answers on Monday, but at least we'll get a financial snapshot for the bulls and bears to update their arguments.
Cytokinetics checks in on Tuesday. The biotech company's lead candidate is a cardiac muscle contractility program that Cytokinetics is trying to get approved for the potential treatment of heart failure. Investors see red ink here, but analysts do see the quarterly deficit narrowing this time around.
JDS Uniphase reports on Wednesday. The optical-networking bellwether is likely to disappoint bulls and bears this time around. Wall Street sees JDS Uniphase merely matching last year's quarterly profit of $0.11 a share.
Acura Pharmaceuticas checks in on Thursday. Drugmakers use Acura's Aversion and Impede technologies to create abuse-deterrent treatments. In short, if an abuser tries to extract the active ingredient of a drug to heighten addictive experiences, Acura's technologies kick in to make the whole dose unusable.
Acura is a small company, but with an average daily trading volume of more than 600,000 shares, it's clear that the stock is generating healthy interest from buyers and sellers.
The market is typically quiet on Friday, but that's certainly not the case during earnings season.
Trex reports on Friday morning. The leading player in wood-alternative decking materials has benefited from a recent home-improvement boom, and it's been easily surpassing Wall Street's profit targets over the past year by double-digit percentage margins. Trex business also tends to pick up this time of year, as homeowners take on projects to replace or build outdoor patio decks as the warm weather kicks in.
The article The Fool Looks Ahead originally appeared on Fool.com.Longtime Fool contributor Rick Munarriz has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Trex and has options on Herbalife. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.